Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Kadmon Holdings Llc (KDMN)

Kadmon Holdings Llc (KDMN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results ACCESS Newswire - Thu Nov 4, 2021

- REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States - - Execution of strategic launch strategy underway; Third...

KDMN : 9.50 (+0.21%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates TGP, ESBK, KDMN, VNE; Shareholders are Encouraged to Contact the Firm ACCESS Newswire - Fri Oct 8, 2021

NEW YORK, NY / ACCESSWIRE / October 8, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Teekay LNG Partners L.P. (NYSE:TGP) concerning...

ESBK : 23.08 (+0.04%)
KDMN : 9.50 (+0.21%)
TGP : 16.98 (-0.06%)
VNE : 36.95 (+0.19%)
Kadmon Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting ACCESS Newswire - Fri Oct 1, 2021

NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein,...

KDMN : 9.50 (+0.21%)
Kadmon Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting ACCESS Newswire - Fri Oct 1, 2021

NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein,...

KDMN : 9.50 (+0.21%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates MDLA, MSON, KDMN, ECHO; Shareholders are Encouraged to Contact the Firm ACCESS Newswire - Fri Sep 24, 2021

NEW YORK, NY / ACCESSWIRE / September 24, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Medallia, Inc. (NYSE: MDLA) concerning potential...

MSON : 26.54 (+4.74%)
ECHO : 48.24 (+0.04%)
MDLA : 33.99 (+0.06%)
KDMN : 9.50 (+0.21%)
Sanofi To Acquire Kadmon To Further Strengthen Growth of Transplant Business ACCESS Newswire - Wed Sep 8, 2021

Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two...

KDMN : 9.50 (+0.21%)
Kadmon Announces U.S. Availability of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD) ACCESS Newswire - Thu Aug 19, 2021

NEW YORK, NY / ACCESSWIRE / August 19, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets is now commercially available for shipment...

KDMN : 9.50 (+0.21%)
Kadmon Provides Business Update and Reports Second Quarter 2021 Financial Results ACCESS Newswire - Thu Aug 5, 2021

NEW YORK, NY / ACCESSWIRE / August 5, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the second quarter of 2021. "The recent...

KDMN : 9.50 (+0.21%)
Kadmon Announces REZUROCK(TM) (belumosudil) Added to National Comprehensive Cancer Network(R) Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation ACCESS Newswire - Wed Aug 4, 2021

NEW YORK, NY / ACCESSWIRE / August 4, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced that the National Comprehensive Cancer Network® (NCCN) added REZUROCKTM (belumosudil) tablets to its NCCN...

KDMN : 9.50 (+0.21%)
Kadmon Announces Pivotal Trial Data Published in the Journal Blood for REZUROCK(TM) (Belumosudil) in Chronic Graft-Versus-Host Disease (cGVHD) ACCESS Newswire - Mon Jul 19, 2021

- REZUROCK is approved by the U.S. FDA for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy - NEW YORK, NY / ACCESSWIRE...

KDMN : 9.50 (+0.21%)

Barchart Exclusives

This Dividend Giant Yielding 4.5% Is Wall Street’s Top Telecom Pick for 2026 Barchart - 24 minutes ago
JPMorgan just released a list of its 47 top stock picks for 2026, but only one comes from the telecom industry, a stock that features an attractive yield and improving cash flow outlook. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot